Skip to main content
Edition No. 102 · GlobalEst. 2026
Nasdaq24,126.87-3.75%FTSE 10010,753.51+0.02%Gold3,879.30-0.15%Nasdaq24,126.87-3.75%FTSE 10010,753.51+0.02%Gold3,879.30-0.15%

U.S. FDA Clears Investigational Drug for ALS Clinical Trial

QurAlis Corporation receives regulatory green light to advance its precision therapeutic for amyotrophic lateral sclerosis.

By Planet Earth News Medicine Desk· Published 2026-11-17· 4 min read
PENN Explainer

Hear this story explained in 90 seconds.

The U.S. Food and Drug Administration has officially cleared an Investigational New Drug application for QRL-201, a new treatment designed for patients with amyotrophic lateral sclerosis. This regulatory milestone allows the developer, QurAlis Corporation, to move forward with a pivotal clinical trial in the United States. The company expects to launch this study, known as the CONQUR trial, in the first half of 2027. This development marks a significant step in the search for therapies that can effectively modify the progression of the disease. Amyotrophic lateral sclerosis, commonly known as ALS, is a progressive neurodegenerative condition that affects nerve cells in the brain and spinal cord. The disease leads to a loss of muscle control, which eventually impacts a patient's ability to move, speak, and breathe. Because the condition is rare and complex, the medical community has long sought treatments that can address the underlying biological causes of the illness. QRL-201 is a precision therapeutic that aims to restore the expression of a specific protein called STATHMIN-2. STATHMIN-2 is essential for maintaining the stability of axons and ensuring proper muscle innervation. In the majority of patients living with ALS, the expression of this protein is significantly reduced due to the loss of a regulatory protein known as TDP-43. By targeting this specific biological pathway, researchers hope to slow the physical decline associated with the disease. This approach represents a shift toward personalized medicine, where treatments are tailored to the specific molecular needs of the patient. Before receiving this clearance, QurAlis completed a dose-range finding phase of its ANQUR clinical trial. The final data from this study showed that the drug was generally safe and well-tolerated by participants. Most adverse events reported during the study were described as mild or moderate, with no serious safety concerns identified. These results provided the necessary evidence to support the transition into more advanced testing phases. Beyond safety, the trial data indicated promising clinical outcomes for those receiving the treatment. Patients in the high-dose group experienced a 50 percent reduction in the progression of functional decline compared to those who received a placebo. This measurement was based on the ALS Functional Rating Scale-Revised, a standard tool used to track the severity of the disease. These findings were statistically significant, suggesting that the drug may have a meaningful impact on patient health. Researchers also observed positive changes in specific biomarkers during the study. The treatment was associated with a 46 percent reduction in phosphorylated neurofilament heavy levels in the cerebrospinal fluid of participants. These proteins serve as indicators of axonal damage, and their reduction suggests that the drug may help protect nerve cells from further harm. Similar reductions were noted in plasma neurofilament light levels, further supporting the potential efficacy of the therapy. "We are delighted to receive FDA clearance of the IND for QRL-201, our lead program in ALS, marking an important milestone for QurAlis and highlighting the Agency’s support for rare diseases like ALS," said Kasper Roet, the CEO and co-founder of QurAlis. The company plans to continue its research efforts across multiple regions to gather more comprehensive data. While the U.S. trial is being prepared, open-label extended dosing is already underway in Canada, the United Kingdom, and the European Union. Medical experts have expressed cautious optimism regarding these developments. Merit E. Cudkowicz, the director of the Sean M. Healey and AMG Center for ALS at Mass General Brigham, noted that the findings justify additional research into the drug. She emphasized that the data provides a strong foundation for exploring QRL-201 as a potential treatment option for individuals with sporadic forms of the disease. Continued collaboration between clinicians and researchers remains a priority as the trial moves forward. The upcoming CONQUR trial will be critical in determining the long-term benefits and risks of the therapy. By expanding the study to a larger population, investigators hope to confirm the results seen in earlier phases and establish a clear path for potential regulatory approval. The design of this pivotal study will likely incorporate the lessons learned from the initial dose-range finding phase. Further details regarding the trial structure and participant criteria are expected to be released in early 2027. As the medical community looks toward the future, the focus remains on improving outcomes for those affected by this debilitating condition. The development of antisense oligonucleotide therapies like QRL-201 highlights the growing role of genetic and molecular research in modern medicine. If successful, this treatment could offer a new way to manage the disease and improve the quality of life for patients worldwide. The progress made by QurAlis serves as a reminder of the ongoing efforts to address unmet needs in neurodegenerative care.

You've reached your free article limit

You've read 10 of 10 free articles this month. Subscribe to Planet Earth News Network for unlimited access to neutral, global journalism — plus puzzles, podcasts, and the weekly newsletter.

Already a subscriber? Sign in.

Ask the Author

Subscribers can ask the journalist a question about this story. Subscribe to ask.

Neutrality note

Auto-harvested from global news wires and presented neutrally by PENN.

Share this article

to vote

Comments

No comments yet — be the first to share your thoughts.

Related stories in Medicine